MétaCan
Menu
Back to cohort
Record W4415293444 · doi:10.1128/aac.00773-25

Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections

2025· article· en· W4415293444 on OpenAlexfundno aff
Eva Benavent, Jaime Lora‐Tamayo, Marta Ulldemolins, Paula Pons‐Oltra, Matthieu Grégoire, Mikel Mancheño‐Losa, Pilar Hernández-Jiménez, María Ángeles Meléndez-Carmona, Victor Casals, Raül Rigo‐Bonnin, Óscar Murillo

Bibliographic record

VenueAntimicrobial Agents and Chemotherapy · 2025
Typearticle
Languageen
FieldMedicine
TopicOrthopedic Infections and Treatments
Canadian institutionsnot available
FundersInstituto de Salud Carlos IIIMedical Research Council CanadaAngelini PharmaFundación Alfonso Martín Escudero
KeywordsDalbavancinDosingPharmacokineticsAntibioticsMinimum inhibitory concentrationPopulationAdverse effect

Abstract

fetched live from OpenAlex

ABSTRACT The efficacy, safety, and population pharmacokinetics of a single 1,500 mg dose of dalbavancin as a sequencing treatment for Gram-positive chronic prosthetic joint infections (CPJIs) have not been described. We present an observational, retrospective study conducted in two Spanish hospitals including patients with CPJI caused by Gram-positive bacteria susceptible to dalbavancin managed with two-stage exchange, antibiotic-loaded spacers, and a single 1,500 mg dose of dalbavancin. Follow-up visits included measurement of dalbavancin plasma concentrations. Negative intraoperative cultures at second-stage surgery defined microbiological cure. Population pharmacokinetics and Monte Carlo dosing simulations were used to evaluate whether this dose provided a therapeutic antibiotic exposure defined as the ratio between the area under the unbound concentration curve and the bacteria minimum inhibitory concentration (ƒAUC 0-24h /MIC) ≥ 50 for the entire treatment period. Twenty patients were included, with CPJI mostly caused by coagulase-negative staphylococci (71%). After 11.5 days of intravenous antibiotic therapy (vancomycin, 75%), patients received 1,500 mg of dalbavancin without adverse events. Microbiological cure was 94.7% (median follow-up, 693 days). Dosing simulations suggest that a single 1,500 mg dose of dalbavancin is sufficient for maintaining ƒAUC 0-24h /MIC ≥ 50 for MIC ≤ 0.25 mg/L for 3–4 weeks after administration. A single 1,500 mg dose of dalbavancin combined with antibiotic-loaded spacers may be an effective and safe sequencing treatment for CPJI and provide 3–4 weeks of therapeutic exposure for susceptible microorganisms. Considering dalbavancin’s unique pharmacokinetics, this approach may be considered in the clinical management of CPJI.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.271
Teacher spread0.259 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAntimicrobial Agents and ChemotherapySame topicOrthopedic Infections and TreatmentsFrench-language works237,207